In patients with active rheumatoid arthritis despite therapy with DMARDs, treatment with a spleen tyrosine kinase inhibitor has achieved similar response rates to those achieved in clinical trials of other drugs, including biologic agents. Where might these agents fit in the current armamentarium against this disease?
This is a preview of subscription content, log in via an institution to check access.
References
Weinblatt, M. E. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303–1312 (2010).
Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309–3318 (2008).
Genovese, M. C. et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis Rheum. doi:10.1002/art.30114.
McInnes, I. B. & O'Dell, J. R. State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 69, 1898–1906 (2010).
Riccaboni, M., Bianchi, I. & Petrillo, P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov. Today 15, 517–530 (2010).
Bajpai, M., Chopra, P., Dastidar, S. G. & Ray, A. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin. Investig. Drugs 17, 641–659 (2008).
Bahjat, F. R. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus Arthritis Rheum. 58, 1433–1444 (2008).
Pine, P. R. et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244–257 (2007).
Rivera, J. & Colbert, R. A. Healing the Syk through kinase inhibitors. N. Engl. J. Med. 363, 1362–1364 (2010).
Jabbour, E., Deininger, M. & Hochhaus, A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia doi:10.1038/leu.2010.215.
Acknowledgements
The authors would like to thank R. Sanmartí for his critical appraisal of the article and D. Buss for his technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Gómez-Puerta, J., Bosch, X. Spleen tyrosine kinase inhibitors—novel therapies for RA?. Nat Rev Rheumatol 7, 134–136 (2011). https://doi.org/10.1038/nrrheum.2011.8
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.8
- Springer Nature Limited
This article is cited by
-
Syk inhibitors in clinical development for hematological malignancies
Journal of Hematology & Oncology (2017)